Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00746746
Recruitment Status : Unknown
Verified September 2008 by Ochsner Health System.
Recruitment status was:  Active, not recruiting
First Posted : September 4, 2008
Last Update Posted : January 13, 2011
NewLink Genetics Corporation
Information provided by:
Ochsner Health System

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : June 2010
Estimated Study Completion Date : June 2011